Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report

Date: February 5, 2016
Pages: 25
Price:
US$ 175.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SD8AE8F9A6AEN
Leaflet:

Download PDF Leaflet

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report
INTRODUCTION

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

FEATURES:
  • Detailed information on Salix Pharmaceuticals, Ltd. required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Salix Pharmaceuticals, Ltd. in the form of a SWOT analysis
  • An in-depth view of the business model of Salix Pharmaceuticals, Ltd. including a breakdown and examination of key business segments
  • Intelligence on Salix Pharmaceuticals, Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
  • News about Salix Pharmaceuticals, Ltd., such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends
HIGHLIGHTS:

Salix Pharmaceuticals (Salix or 'the company') is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs include Xifaxan, Osmoprep and Metozolv ODT. Salix primarily operates in the US, where it is headquartered in Raleigh, North Carolina. It employed about 1,000 people as of December 31, 2014. The company recorded revenues of $1,133.5 million during the financial year ended December 2014 (FY2014), an increase of 24% over FY2013. The operating loss of the company was $490.1 million in FY2014, as compared to an operating profit of $252.3 million in FY2013. The net loss of the company was $414.9 million in FY2014, as compared to a net profit of $130.8 million in FY2013.

REASONS TO PURCHASE:
  • Gain understanding of Salix Pharmaceuticals, Ltd. and the factors that influence its strategies
  • Track strategic initiatives of the company and latest corporate news and actions
  • Assess Salix Pharmaceuticals, Ltd. as a prospective partner, vendor or supplier
  • Support sales activities by understanding your customers' businesses better
  • Stay up to date on Salix Pharmaceuticals, Ltd.’s business structure, strategy and prospects
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services
Skip to top


Ask Your Question

Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: